Block Listing Review and TVR

RNS Number : 7890K

ReNeuron Group plc

02 September 2019

 

 

2 September 2019

AIM: RENE

ReNeuron Group plc

("ReNeuron" or the "Company")

Block Listing Review and Total Voting Rights

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, provides the following update in accordance with Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements.

Name:	ReNeuron Group plc
Name of Scheme:	ReNeuron Share Option Schemes
Period of Return:	From 1 March 2019  to 31 August 2019
Balance of unallotted securities under scheme(s) from previous return:	902,825 Ordinary Shares (of 1p each)
Plus: The amount by which the block scheme(s) has been increased since the date of the last Review (if any increase has been applied for):	N/A
Less: Number of securities issued/allotted under scheme(s) during period	186,084
Equals: Balance under scheme(s) not yet issued/allotted at end of period:	716,741 Ordinary Shares
Number and class of securities originally admitted and the date of admission:	20,000 ordinary shares on 13 May 2010

Total Voting Rights

At 31 August 2019, the Company had 31,832,270 ordinary shares in issue, each carrying one voting right. As the Company holds no ordinary shares in treasury, the figure of 31,832,270 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change in their interest in, the Company under the FCA's Disclosure and Transparency Rules.

ENDS

ENQUIRIES:

ReNeuron	[phone]
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan	[phone]
Mark Court, Sophie Wills, Tilly Abraham
Stifel Nicolaus Europe Limited	[phone]
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Joint Broker)
N+1 Singer	[phone]
Aubrey Powell, James Moat, Mia Gardner (Joint Broker)

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs.  The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa and for disability as a result of stroke.  ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action.  ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.  For further information visit www.reneuron.com.

 

END

 

 

MSCBLGDIBXXBGCG